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Abstract
RB1-inducible coiled-coil 1 (RB1CC1; also known as FIP200) plays important roles in several biological pathways such as cell
proliferation and autophagy. Evaluation of RB1CC1 expression can provide useful clinical information on various cancers
and neurodegenerative diseases. In order to realize the clinical applications, it is necessary to establish a stable supply of
antibody and reproducible procedures for the laboratory examinations. In the present study, we have generated mouse
monoclonal antibodies for RB1CC1, and four kinds of antibodies (N1-8, N1-216, N3-2, and N3-42) were found to be optimal
for clinical applications such as ELISA and immunoblots and work as well as the pre-existing polyclonal antibodies. N1-8
monoclonal antibody provided the best recognition of RB1CC1 in the clinico-pathological examination of formalin-fixed
paraffin-embedded tissues. These monoclonal antibodies will help to generate new opportunities in scientific examinations
in biology and clinical medicine.
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Introduction
RB1-inducible coiled-coil 1 (RB1CC1: the symbol used here,
which is approved by the Human Genome Organization
[HUGO] Gene Nomenclature Committee; it is also known as
FIP200, focal adhesion kinase family-interacting protein of
200 kDa) plays an important role through its interaction with
various molecules in several cell signaling pathways. RB1CC1 is a
positive regulator of the NF-kb signaling pathway [1,2] and
mTOR [1,3,4]. RB1CC1 also functions as a negative factor in
FAK-Erk1/2 signaling [5,6]. Importantly, RB1CC1 has been
identified recently as a mammalian homolog of Atg17 in the
autophagy pathway [7,8,9,10,11].
In mammalian cell nuclei, RB1CC1 forms a complex with p53
and/or hSNF5, and the large protein complex works as a strong
activator of RB1, p16, and p21 promoters [12,13,14,15,16]. Thus,
nuclear RB1CC1 enhances the RB1 pathway globally and
behaves as a tumor suppressor in some types of human
malignancies [17,18].
RB1CC1 has been established as a prognostic predictor in
breast and salivary cancer patients [17,18]. Thus, a nuclear
RB1CC1 expression has been revealed to be fundamentally
related to better prognoses in breast and salivary cancers.
Furthermore, the combined evaluation of RB1CC1, RB1, and
p53 can significantly predict a longer disease-specific survival
[17,18]. Therefore, evaluation of RB1CC1 expression combined
with RB1 and p53 status would provide useful information in
clinical practice and help the planning of future therapeutic
strategies in various human cancers.
In order to make the clinical evaluation of RB1CC1 generally
available and to clarify more precisely its biological function,
specific antibodies must react reproducibly in various laboratory
experiments and be available as a stable supply to clinics and
scientific laboratories. Here, we describe the production of mouse
monoclonal antibodies that function as well as the preexisting
polyclonal antibodies [3,10,12,17,18,19,20] in various experimen-
tal and clinical applications; and one of these monoclonal
antibodies appears to be particularly suitable for the clinical
pathological evaluation of formalin-fixed paraffin-embedded tissue
sections.
Results and Discussion
In order to generate mouse monoclonal antibodies that
recognize RB1CC1, we prepared polypeptides of residues 25–
271 (N1) and 549–819 (N3) of RB1CC1 and used them as
immunogens (Fig. 1). Each antigen-specific antibody was screened
by ELISA, and 112 antibodies for the epitopes within N1 and 58
antibodies for the epitopes within N3 were produced. Among 170
antibodies screened by ELISA, four antibodies were selected by
their strong immunoreactivity against ,200 kDa full-length
human RB1CC1 and little cross-reactivity with other proteins in
immunoblots. These four antibodies were named N1-8, N1-216,
N3-2, and N3-42. In immunoblots, it was confirmed that these
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specifically and stronger than the previously reported polyclonal
antibodies [3,10,12,17,18,19,20] (Fig. 2–3). These antibodies were
also more specific than a commercially available one
(#MAB8738; Abnova), recognizing some non-specific signals,
and were utilized for the signal sensitivities by mixing them (Fig. 3).
To identify precisely each epitope for the monoclonal
antibodies, we performed epitope mapping using ,27–56 kDa
smaller mutant peptides generated with stop-codon in N1 or N3
polypeptides. According to the detection of immunoreactivities,
N1-8 did not recognize amino acid (aa) residues 25–254, but
reacted only with aa residues 25–271 of N1 (Fig. 4). Therefore,
N1-8 could recognize an epitope located within the 255–271 aa
residues of RB1CC1. Similar strategic experiments suggested that
N1-216, N3-2, and N3-42 could recognize epitopes located within
the 235–254, 715–734, and 715–734 aa residues, respectively, of
RB1CC1.
In order to find the most useful antibody for clinical
pathological applications, we evaluated the immunoreactivities of
these four kinds of monoclonal antibodies in formalin-fixed
paraffin-embedded tissue sections, comparing the reactivities with
that of the pre-existing polyclonal antibody [3,10,12,17,18,19,20].
Among the four monoclonal antibodies, N1-8 had the strongest
immunoreactivity in formalin-fixed paraffin-embedded tissue
sections, and non-specific reaction was negligible. Therefore, we
compared the immunoreactivity of N1-8 monoclonal antibody
with that of the rabbit polyclonal antibody [3,10,12,17,18,19,20]
using breast cancer tissues. N1-8 monoclonal antibody had a
similar immunoreactivity as that of the polyclonal antibody in
formalin-fixed paraffin-embedded breast cancer tissue sections
containing non-neoplastic mammary ductal epithelium. In non-
neoplastic ductal epithelium, both cytoplasm and nuclei were
similarly stained with these two antibodies. As reported previously
[12,17,18,20], there were three types of staining variations in
breast cancer samples: I, negative staining in both cytoplasm and
nuclei; II, positive staining only in cytoplasm; III, positive staining
only in nuclei or in nuclei and cytoplasm. N1-8 monoclonal and
the polyclonal antibodies reacted similarly to RB1CC1 in the
formalin-fixed paraffin-embedded breast cancer tissue samples
(Fig. 5).
In a series of 57 clinical cases of breast cancer, immunoreactive
variations between N1-8 monoclonal and the pre-existing
polyclonal antibodies were precisely evaluated. Although N1-8
could recognize cytoplasmic RB1CC1 better than the polyclonal
antibodies, both antibodies reacted identically with nuclear
RB1CC1 (Table 1), which can predict a better long-term
prognosis of breast and salivary cancer patients [17,18,20]. N1-8
appears to be best adapted to the clinical pathological evaluation
of RB1CC1 expression in human pathological disorders, such as
various cancers and neurodegenerative diseases.
In conclusion, we have produced four kinds of monoclonal
antibodies that can specifically recognize and quantify RB1CC1 in
examinations such as ELISA and immunoblots. One monoclonal
antibody (N1-8) had the best ability to recognize RB1CC1 in
formalin-fixed paraffin-embedded tissue sections; this antibody can
be supplied stably to clinico-pathological laboratories.
Materials and Methods
Immunization and preparation of hybridomas
In order to prepare immunogens, two kinds of recombinant
partial fragments of RB1CC1 were produced in BL21 E. coli. N1
consisted of aa residues 25–271 and contained the NH2-terminal
glutathione-S-transferase (GST); N3 consisted of aa residues 549–
819 and similarly contained the NH2-terminal GST. Each of them
also contained the COOH-terminal polypeptide fragment of
RB1CC1 (GenBank accession No. NP_055596). N1 and N3,
whose molecular weights were 54 and 56 kDa, were used as
immunogens after purification via SDS-polyacrylamide gel
electrophoresis (SDS-PAGE). BALB/C mice were immunized
with these purified proteins in complete Freund’s adjuvant.
Figure 1. A schematic representation of RB1CC1, immunogens, and epitope sites for four kinds of monoclonal antibodies (N1-8,
N1-216, N3-2, and N3-42). Two recombinant polypeptides of RB1CC1 containing amino acid (aa) residues 25–271 (N1) and 549–819 (N3),
respectively, were used as immunogens. N1-216, N1-8, N3-2, and N3-42 antibodies recognize epitopes within aa residues 235–254, 255–271, 715–734,
and 715–734, respectively, of RB1CC1.
doi:10.1371/journal.pone.0032052.g001
Figure 2. Immunoblot analysis of four monoclonal antibodies
and pre-existing polyclonal antibodies. Four kinds of monoclonal
antibodies (N1-8, N1-216, N3-2, and N3-42) showed strong immunore-
activity for ,200 kDa full-length human RB1CC1 and little cross-
reactivity with other proteins in Western blot analysis. Two kinds of pre-
existing polyclonal antibodies (N1-poly and N3-poly) were used to the
blotting control. Four mg of protein lysates of HEK293 and the cells
overexpressing RB1CC1 were applied to the analysis. An arrowhead
shows the position of ,200 kDa full-length human RB1CC1.
doi:10.1371/journal.pone.0032052.g002
RB1CC1 Monoclonal Antibody
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body were first screened by ELISA and then by Western blot
analysis.
Western blot analysis
HEK 293 cells and cells overexpressing RB1CC1, which had
been transiently transduced with pcDNA3.1-RB1CC1 [13], were
lysed for Western blotting, as described by Sarbassov et al [21].
After clearing lysed materials by centrifugation at 15,0006 g for
10 min, the supernatants were boiled in SDS sample buffer.
Proteins resolved by SDS-PAGE were transferred to polyvinyli-
dene difluoride (PVDF) filters. After blocking of the filters with
TBS-T (10 mM Tris-HCl (pH 7.6), 150 mM sodium chloride,
0.1% Tween 20) containing 5% bovine serum albumin (BSA), the
filters were incubated overnight with the primary antibodies (2–
4 mg/ml IgG) in TBS-T containing 2% BSA at 4uC. The filters
were then washed in TBS-T and incubated for 1 h in horseradish
peroxidase-conjugated anti-mouse IgG diluted 1:10,000 in TBS-T
containing 2% BSA. After several washes with TBS-T, the
immunoreactivity was detected using the ECL system (GE
Healthcare, UK) according to the procedures recommended by
the manufacturer.
Totals of 112 and 58 mouse monoclonal antibodies specifically
reacted with N1 and N3 polypeptides, respectively, in ELISA.
Four antibodies were additionally selected by immunoreacti-
vity for ,200 kDa full-length RB1CC1 in immunoblots.
These antibodies have been named N1-8, N1-216, N3-2, and
N3-42 in the present study, and they are presently available for
commercial purchase (Mikuri Immunology Laboratory, Osaka,
Japan).
Comparison between monoclonal and polyclonal
antibodies for RB1CC1
The cancer cell lines, HeLa (endocervical carcinoma), MCF7,
T47D, and SKBr3 (breast carcinoma) were purchased from
American Type Culture Collection. TIG-108 human normal
fibroblast was from the Japanese Collection of Research
Bioresources. These cell lines were cultured in Dulbecco’s
modified Eagle’s medium or RPMI 1640 containing 10% FBS.
All cell culture media were supplemented with penicillin (50 units/
mL) and streptomycin (50 mg/mL). These cell lines were
incubated at 37uC in a humidified chamber supplemented with
5% CO2. Endogenous RB1CC1 expressions of each cell line were
evaluated by Western blotting using 4 kinds of mouse monoclonal
antibodies (N1-8, N1-216, N3-2 and N3-42), a commercially
Figure 3. Comparison between monoclonal and polyclonal
antibodies for RB1CC1. Western blot analyses using 4 kinds of
monoclonal (N1-8, N1-216, N3-2 and N3-42), one commercially available
monoclonal (#MAB8738; Abnova), and 2 kinds of polyclonal (N1-poly
and N3-poly) antibodies for RB1CC1 are demonstrated in various cell
lines. Twenty mg of each cell protein was loaded in each lane of the SDS-
PAGE. Twenty, ten and four mg of proteins of HEK293 and the cells
overexpressing RB1CC1 were also loaded. a-tubulin was used as a
blotting control for protein mounts. The automatically exposure time
(ImageQuant
TM LAS-4000; Fujifilm, Japan) was indicated at right ends.
Arrow, arrowhead and * indicate 250, 150 kDa and full-length RB1CC1,
respectively.
doi:10.1371/journal.pone.0032052.g003
Figure 4. CBB staining and immunoblot analysis of four kinds
of monoclonal antibodies (N1-8, N1-216, N3-2, and N3-42). N1-
8 did not recognize aa residues 25–254, but recognized aa residues 25–
271 of N1. Therefore, N1-8 was considered to recognize an epitope
located among aa residues 255–271 of RB1CC1. Similarly, N1-216, N3-2,
and N3-42 recognized epitopes located among aa residues 235–254,
715–734, and 715–734, respectively. The recombinant mutant proteins
(,27–56 kDa) of N1 and N3 were confirmed by anti-GST immunoblots.
Coomassie Brilliant Blue (CBB) staining of each protein band in
polyacrylamide gel electrophoresis is shown in the lowest row. Arrows
and arrowheads indicate 47 and 39 kDa, respectively.
doi:10.1371/journal.pone.0032052.g004
RB1CC1 Monoclonal Antibody
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existing rabbit polyclonal antibodies (N1-poly and N3-poly)
[3,10,12,17,18,19,20]. ImageQuant
TM LAS-4000 (Fujifilm, Japan)
automatically transferred the blotting signals to digital images,
referring to the intensities. The automatically exposure time was
inversely reflected to the maximum signal of each blot.
Two kinds of anti-RB1CC1 polyclonal antibodies (N1-poly and
N3-poly) were generated in our laboratory as described previously
[3,12,19]. Briefly, 2 kinds of NH2-terminal GST-fusion proteins
containing aa residues 25–271 (N1) and 549–819 (N3) of RB1CC1
were used as immunogens in rabbits. IgG fractions were purified
from rabbit antisera, and applied to the experiments with 1–2 mg/
ml as polyclonal antibodies for RB1CC1.
Epitope mapping
Epitope mapping experiments were performed to detect the
antigen epitopes for each of the selected four monoclonal
antibodies. We artificially introduced stop codons into the N1
and N3 peptides. Plasmids containing each of the mutated N1 or
N3 peptides were then transfected into BL21 E. coli and
expressed: ,27–54 kDa N1 mutant polypeptides comprised
residues 25–34, 25–54, 35–74, 25–94, 25–114, 25–134, 25–154,
25–174, 25–194, 25–214, 25–234, 25–254, and 25–274; ,29–
56 kDa N3 mutant polypeptides comprised residues 549–574,
549–594, 549–614, 549–634, 549–654, 549–674, 549–694, 549–
714, 549–734, 549–754, 549–774, 549–794, 549–814, and 549–
819. The proteins were lysed in 16Laemmli’s SDS sample buffer.
Two sets of sample proteins that were translated from these
mutants were prepared and resolved by SDS-PAGE. Then, one
set of the samples was stained by Coomassie Brilliant Blue (CBB)
using Quick-CBB PLUS (Wako; Osaka, Japan), and another set
was transferred to a PVDF filter. The filter was immunoblotted
with four different monoclonal antibodies (N1-8, N1-216, N3-2,
and N3-42) and anti-GST antibody.
Figure 5. Comparison of immunoreactivities between N1-8 monoclonal and N1 polyclonal anti-RB1CC1 antibodies in formalin-
fixed paraffin-embedded breast cancer tissues. In non-neoplastic mammary ductal epithelium, cytoplasm and nuclei were similarly stained
with these two antibodies. In breast cancer tissue samples, these two antibodies reacted similarly in all types of staining variation (I, negative staining
in both cytoplasm and nuclei; II, positive staining only in cytoplasm; III, positive staining only in nuclei or in nuclei and cytoplasm). I–II and III were
defined as RB1CC1 -negative and -positive, respectively, in the previous clinical cohorts. Bar, 100 mm.
doi:10.1371/journal.pone.0032052.g005
RB1CC1 Monoclonal Antibody
PLoS ONE | www.plosone.org 4 March 2012 | Volume 7 | Issue 3 | e32052Immunohistochemistry
To evaluate the reactivities of anti-RB1CC1 monoclonal
antibodies with human breast cancer tissues, histological speci-
mens from 57 cases were used in this study. The formalin-fixed
paraffin-embedded tissue samples were serially sliced into 5-mm
sections. Deparaffinized sections were heated by autoclaving
(120uC, 1 min) or ImmunoSaver
TM (Nissin EM Ltd., Japan;
98uC, 45 min), immersed in 0.3% H202 and rinsed with 16PBS
before incubation overnight at 4uC with each of the anti-RB1CC1
primary antibodies, rabbit polyclonal antibodies (N1-poly and N3-
poly) [3,10,12,17,18,19,20] and mouse monoclonal antibodies
(N1-8, N1-216, N3-2, and N3-42). The sections were rinsed with
16PBS and incubated with the secondary antibody (Simple Stain
MAX-PO; Nichirei, Japan) at room temperature for 1 h. The
sections were then stained with 3,39-diaminobenzidine tetrahy-
drochloride (DAB), and counter-stained with hematoxylin.
Microscopic evaluation
As previously described [12,17,18,20], the immunohistochem-
ical results for RB1CC1 were first classified into three categories: I,
negative staining in both cytoplasm and nuclei; II, positive staining
only in cytoplasm; III, positive staining only in nuclei or in nuclei
and cytoplasm. Then, RB1CC1 staining grade I–II and III were
defined as ‘‘negative (2)’’ and ‘‘positive (+),’’ respectively; i.e., only
the cases with nuclear RB1CC1 expression were recognized as
RB1CC1(+). Among four kinds of monoclonal antibodies, N1-8
reacted better than the others with formalin-fixed paraffin-
embedded tissue sections, so it was applied to compare the clinical
utility of a monoclonal antibody with that of an anti-RB1CC1 pre-
existing polyclonal antibody [3,10,12,17,18,19,20] in 57 breast
cancer cases.
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Table 1. Summary of immunoreactive variations between
N1-8 monoclonal and polyclonal antibodies in a series of 57
clinical breast cancer cases.
N1-8 monoclonal
(2) (+) Cases
cytoplasm
(2)( +)
N1-polyclonal
cytoplasm
(2) (2)4 5 0 9
(+)2 8 0 1 0 1 9
(+) 00 3 8 3 8
61 3
19 38 57
Although N1-8 could recognize cytoplasmic RB1CC1 better than the polyclonal
antibody (13 vs 10 cases), both antibodies were completely consistent in
recognizing the nuclear reactivity of RB1CC1.
doi:10.1371/journal.pone.0032052.t001
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